Farmacia italiana online: acquisto cialis in Italia e Roma senza ricetta.

Pmt form selection

AF Patient Management Tool
October 2013
PMT FORM SELECTION: Atrial Fibrillation
Legend: Elements in bold are required
Patient ID:
ARRIVAL AND ADMISSION INFORMATION
Internal Tracking ID:
Arrival Date and Time:
Admit Date:
Ο 1 Non-Health Care Facility Point of Origin Point of Origin
for Admission or
Ο 4 Transfer From a Hospital (Different Facility) Ο 5 Transfer from a Skilled Nursing Facility (SNF) or Intermediate Ο F Transfer from Hospice and is Under a Hospice Plan of Care or Enrolled in a Hospice Program Was patient admitted as inpatient? Ο Yes Ο No
If not admitted, was the patient observation status? DEMOGRAPHIC DATA
Date of Birth:
Hispanic Ethnicity: Ο Yes Ο No/UTD
 Mexican, Mexican American, Chicano/a  Another Hispanic, Latino or Spanish Payment Source:
Patient Postal Code:
MEDICAL HISTORY
Medical History
(Select all that
Labile INR (Unstable/high INRs or time in therapeutic range <60%)? Other risk factors
Ο No
Ο Unable to determine from the information available in the medical record
NOT FOR USE WITHOUT PERMISSION. 2013 American Heart Association and Outcome Sciences, Inc. a Quintiles Company.
For questions, call 888-526-6700

AF Patient Management Tool
October 2013
Prior Major Bleeding or Predisposition to Bleeding (bleeding diathesis, anemia, etc.)? Ο Yes
Ο No
Ο Unable to determine from the information available in the medical record
Procedures:
DIAGNOSIS
Ο Atrial Fibrillation
Ο Atrial Flutter
Atrial Arrhythmia Type:
Ο Permanent/long standing Persistent Atrial Fibrillation Was Atrial Fibrillation/Flutter the
patient’s primary diagnosis?
If no, what was the patient’s primary
diagnosis?
Were any of the following first detected on
this admission?
MEDICATIONS AT ADMISSION
 Patient on no meds prior to admission  ACE inhibitor  Aldosterone Antagonist  Alpha Blockers Medications Used Prior to
Admission
 rivaroxaban (Xarelto)  lepirudin (Refludan)  Other Anticoagulant EXAM/LABS AT ADMISSION
Presenting symptoms related  Exercise intolerance NOT FOR USE WITHOUT PERMISSION. 2013 American Heart Association and Outcome Sciences, Inc. a Quintiles Company.
For questions, call 888-526-6700

AF Patient Management Tool
October 2013
Heart Rate
Blood Pressure
_________ / _________ mmHg (systolic/diastolic)  Not documented Initial Presenting
Rhythm(s)
Select all that apply
If paced,
underlying Atrial

Rhythm
If paced, pacing

Resting Heart Rate (bpm)_____  Not Available QRS duration (ms) _______  Not Available Initial EKG findings:
PR interval (ms) _______  Not Available Platelet Count
________ mL/min (auto-calculated) Hemoglobin
___________ mg/dL
IN-HOSPITAL CARE
If A-Fib or A-Flutter Ablation selected above: Procedures this
hospitalization
 Cardioversion (check all that apply below)  CRT-D (cardiac resynchronization therapy w/ICD) EF – Quantitative
Obtained:
Ο W/in the last year Ο > 1 year ago Ο Not applicable Ο Normal or mild dysfunction Qualitative moderate/severe dysfunction NOT FOR USE WITHOUT PERMISSION. 2013 American Heart Association and Outcome Sciences, Inc. a Quintiles Company.
For questions, call 888-526-6700

AF Patient Management Tool
October 2013
CHADS2 reported?
If yes, total reported score
in medical record
CHADS2 Risk Factors
Prior stroke or TIA assessed Ο Yes Ο No Assessed
Medical reason(s) documented by a physician, nurse practitioner,
or physician assistant for not assessing risk factors
DISCHARGE INFORMATION
Discharge Date/Time
1 – Home 2 – Hospice – Home 3 – Hospice – Health Care Facility What was the patient’s discharge
disposition on the day of
discharge?
6 – Expired 7 – Left Against Medical Advise/AMA 8 – Not Documented or Unable to Determine (UTD) If Other Health Care Facility
Ο Inpatient Rehabilitation Facility (IRF) When is the earliest physician/APN/PA documentation
of comfort measures only?
BP-Supine
_________ / _________ mmHg (systolic/diastolic)  Not documented Heart Rate
Reason documented by a physician, nurse practitioner, or physician
assistant for discharging patient with heart rate >110 bpm?
Discharge Rhythm(s) (closest to discharge) NOT FOR USE WITHOUT PERMISSION. 2013 American Heart Association and Outcome Sciences, Inc. a Quintiles Company.
For questions, call 888-526-6700

AF Patient Management Tool
October 2013
Resting Heart Rate (bpm)_________  Not Available DISCHARGE MEDICATIONS
Prescribed?
Contraindicated?
Prescribed?
Contraindicated?
Prescribed?
Contraindicated?
Prescribed?
Medication:
Were Dofetilide or Sotalol newly initiated or dose
increased this hospitalization?
If yes, was a QT interval documented after 5 doses and

prior to discharge?
Contraindicated?
Prescribed?
Class: Medication:
Contraindicated?
Are there any
relative or absolute
contraindications to  Occupational risk
oral anticoagulant
therapy? (Check all
that apply)
Prescribed?
Contraindicated?
Prescribed?
Contraindicated?
Prescribed?
Contraindicated?
Prescribed?
Contraindicated?
NOT FOR USE WITHOUT PERMISSION. 2013 American Heart Association and Outcome Sciences, Inc. a Quintiles Company.
For questions, call 888-526-6700

AF Patient Management Tool
October 2013
Prescribed?
Contraindicated?
Prescribed?
Contraindicated?
Prescribed?
Contraindicated?
RISK INTERVENTIONS
Smoking Cessation Counseling Given
Ο Yes Ο No Ο Rhythm Control Strategy Planned Rhythm Control/Rate Control Strategy
Planned/Intended
Ο No Documentation of Strategy
 All were addressed (Check all yes)
Patient and/or caregiver received education
and/or resource materials regarding all of the
following:
Anticoagulation Therapy Education Given
PT/INR Planned Follow-up
Ο Home INR Monitoring Ο Anticoagulation Warfarin Clinic Who will be following patients INR?
Ο Managed by Physician associated with hospital Ο Managed by outside physician Ο Not documented Date of INR test planned post discharge:
____/____/______  Not documented
System Reason for no PT/INR Planned
Follow-up?
Ο Yes Ο No Ο Not Documented Ο Not Applicable Ο Yes Ο No Ο Not Documented Ο Not Applicable Ο Yes Ο No Ο Not Documented Ο Not Applicable Screening for obstructive sleep apnea (Berlin Ο Yes Ο No Ο Not Documented Ο Not Applicable Questionnaire) Referral for evaluation of obstructive sleep Ο Yes Ο No Ο Not Documented Ο Not Applicable Discharge medication instruction provided Ο Yes Ο No Ο Not Documented Ο Not Applicable OPTIONAL FIELDS
ICD-9 Principal Diagnosis Code
____________
NOT FOR USE WITHOUT PERMISSION. 2013 American Heart Association and Outcome Sciences, Inc. a Quintiles Company.
For questions, call 888-526-6700

AF Patient Management Tool
October 2013
___________ Date:___/___/_____  Date UTD 1. ________ Date:___/___/_____  Date UTD 2. ________ Date:___/___/_____  Date UTD 3. ________ Date:___/___/_____  Date UTD 4. ________ Date:___/___/_____  Date UTD 5. ________ Date:___/___/_____  Date UTD _____________
During this hospital stay, was the patient enrolled in a clinical trial in which patients with the same condition NOT FOR USE WITHOUT PERMISSION. 2013 American Heart Association and Outcome Sciences, Inc. a Quintiles Company.
For questions, call 888-526-6700

AF Patient Management Tool
October 2013
CHADS2 Calculation Tool (found on IN HOSPITAL Tab)
(Enabled if “No” is selected for CHADS2 Reported (in medical record)?)  Prior stroke or TIA  Age> 75  Hypertension  Diabetes  Congestive Heart Failure OTHER RISK SCORES
NOTE: CHADS2-VASc is an extension of the CHADS2 score. It contains additional risk categories and can be used as a
complimentary tool in the assessment of thromboembolic risk in atrial fibrillation patients. The AHA/ACC Guidelines
support the use of the CHADS2 score in assessment of thromboembolic risk and indication for anticoagulation therapy
is stratified using the CHADS2 score.

 Congestive Heart Failure  Hypertension (blood pressure consistently above 140/90 or treated with hypertension medication)  Age> 75  Diabetes  Prior stroke/TIA/Thromboembolism  Vascular Disease History (CAD, Prior MI, or PAD)  Female Gender
Adapted from a methodology used by the American College of Chest Physicians:
Lip GY, Niewlatt R, Pisters R, Lane DA, Crijns HJ, et al.
Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach:
the euro heart survey on atrial fibrillation. CHEST 2010 Feb;137(2):263-72. doi: 10.1378/chest.09-1584. Epub 2009 Sep 17.

DISCLAIMER: These tools (ATRIA and HAS-BLED) are presented for informational purposes only and not as an
endorsement of their use in clinical decision making. Many of the same risk factors for warfarin-related
hemorrhage are also risk factors for AF-associated ischemic stroke. The use of these tools as an exclusion for
anticoagulation is not part of AHA/ACC guideline-recommended care for patients with AF. Additionally, some of
the component elements in the HAS-BLED score, such as Labile INR and Prior Major Bleeding or Pre-Disposition
to Bleeding may be difficult to reliably ascertain from the information available in the health record. The HAS-
BLED score should be interpreted with this in mind.

 Anemia (Defined as Hemoglobin < 13 g/dL in men and < 12 g/dL in women)  Severe Renal Disease (defined as a GFR < 30ml/min or on dialysis)  History of Hypertension  Prior hemorrhage (intracranial, gastrointestinal, other hemorrhage) Adapted from a methodology used by the American College of Cardiology: Fang MC, Go AS, Chang Y, et al. A New Risk Scheme to Predict Warfarin-Associated Hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58(4):395-401. doi:10.1016/j.jacc.2011.03.03 NOT FOR USE WITHOUT PERMISSION. 2013 American Heart Association and Outcome Sciences, Inc. a Quintiles Company.
For questions, call 888-526-6700

AF Patient Management Tool
October 2013
 Hypertension History (uncontrolled, >160 mmHg systolic)  Renal Disease (Dialysis, transplant, Cr >2.6 mg/dL or >200 µmol/L)  Liver Disease (Chronic Hepatic Disease, including (e.g.) Cirrhosis, Bilirubin >2x Normal, AST/ALT/AP >3x Normal)  Stroke History  Prior Major Bleeding or Predisposition to Bleeding (bleeding diathesis, anemia, etc.)  Labile INR (Unstable/high INRs or time in therapeutic range <60%)  Age > 65  Medication Usage Predisposing to Bleeding (Antiplatelet agents, NSAIDs)  Alcohol Usage History (>20 units per week) Adapted from a methodology used by the American College of Chest Physicians: Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HM, Lip GH. A novel user-friendly score (has-bled) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey. Chest, 2010;138(5):1093-1100. NOT FOR USE WITHOUT PERMISSION. 2013 American Heart Association and Outcome Sciences, Inc. a Quintiles Company.
For questions, call 888-526-6700

Source: http://strokeondemand.net/idc/groups/heart-public/@wcm/@private/@hcm/@gwtg/documents/downloadable/ucm_457482.pdf

Microsoft powerpoint - euroresidue_2012

Multi residue method for the detection of antimicrobial agents in Dried Distillers Grains by liquid chromatography-high resolution mass spectrometry George Kaklamanos and Ursula Vincent European Commission – DG Joint Research Centre, IRMM, Retieseweg 111, B-2440 Geel, BelgiumIntroductionDried Distillers Grains (DDGs) are produced as a co-product from bio-ethanol production from grain. It is

The impact of marijuana use on glucose, insulin, and insulin resistance among us adults

The Impact of Marijuana Use on Glucose, Insulin, andInsulin Resistance among US AdultsElizabeth A. Penner, BS,,Hannah Buettner, Murray A. Mittleman, MD, ,aUniversity of Nebraska College of Medicine, Omaha; bDepartment of Epidemiology, Harvard School of Public Health, Boston, Mass;cCardiovascular Epidemiology Research Unit, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Mass.

Copyright © 2010-2014 Pdf Pills Composition